AEON Biopharma (AEON) Cash from Investing Activities (2021 - 2025)

AEON Biopharma has reported Cash from Investing Activities for 4 years, with the latest figure at -$4000.0 in Q1 2025.

• Quarterly Cash from Investing Activities changed N/A year-over-year to -$4000.0 in Q1 2025, while the trailing twelve-month figure through Dec 2025 was -$4000.0 (changed N/A YoY) and the FY2025 annual result came in at -$4000.0, changed N/A from the prior year.
• Cash from Investing Activities retreated to -$4000.0 in Q1 2025 per AEON's latest filing, from $80346.0 in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $260.0 million in Q1 2023 and troughed at -$276.0 million in Q1 2021.
• A 4-year average of -$2.3 million and a median of -$4000.0 in 2025 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities surged 100.03% in 2022, then surged 322897.54% in 2023.
• Over 4 years, Cash from Investing Activities stood at -$276.0 million in 2021, then surged by 100.0% to -$9000.0 in 2022, then surged by 992.73% to $80346.0 in 2023, then tumbled by 104.98% to -$4000.0 in 2025.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$4000.0, $80346.0, and $260.0 million for Q1 2025, Q2 2023, and Q1 2023 respectively.